Communiqués MediciNova, Inc.

Actions

MNOV

US58468P2065

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 03/09/2026			Varia. 5j.	Varia. 1 janv.
1,620 ^USD	+13,29%		+14,08%	+23,66%

13/08	MediciNova, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
15/07	MediciNova atteint l’objectif d’inclusion dans l’étude SEANOBI-ALS évaluant MN-166 (ibudilast) chez des patients atteints de SLA	CI

Communiqués

15/08	Maxim Group – 2Q26 Review & Outlook: Multiple Near-Term Events with Readouts in ALS and Metabolic Disease – August 14, 2026	PU
15/08	MediciNova : H.C. Wainwright & Co. – Advancing Dual-Asset Pipeline with Two Key Readouts on the Horizon; 2Q26 Results – August 14, 2026	PU
13/08	MediciNova: Q2 Earnings Snapshot	AQ
15/07	MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients	GL
15/07	MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients	AQ
30/06	MediciNova CEO Provides Shareholder Update	GL
08/06	MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment	GL
27/05	MediciNova Announces Completion of Last Patient Last Visit in the MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)	GL
15/05	MediciNova: Q1 Earnings Snapshot	AQ
28/04	New Peer‑Reviewed Study Reveals Actionable Immune–Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation	GL
16/03	MediciNova to Participate at the 38th Annual ROTH Conference	GL
20/02	MediciNova: Q4 Earnings Snapshot	AQ
30/01	MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients	GL
06/01	2026 New Year’s Greetings from the CEO	GL
06/01	2026 New Year’s Greetings from the CEO	AQ
18/12	MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy	GL
08/12	MediciNova Announces Update and Basic Characteristic Randomized Patients’ of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND	GL
02/12	Message from the CEO to MediciNova Shareholders	GL
18/11	MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor	GL
12/11	MediciNova: Q3 Earnings Snapshot	AQ
07/11	MediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awards	GL
04/11	MediciNova Announces Completion of Patient Enrollment in MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)	GL
31/10/25	MediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed Publication	GL
06/10/25	MediciNova to Present at the LD Micro Main Event XIX Investor Conference	GL
22/09/25	MediciNova Announces Completion of Patient Enrollment in COMBAT-ALS Phase 2b/3 Clinical Trial of MN-166 (ibudilast)	GL